Novartis AG said on Friday that a patient who had been treated with its multiple-sclerosis (MS) drug Gilenya was recently diagnosed with a rare and usually fatal brain disease. The Swiss drug manufacturer said that the patient (whose identity has not been disclosed) was previously treated with the MS drug Tysabri, which is co-marketed by [...]
Novartis Gilenya Patient Develops Rare and Fatal Brain Disease is a post from: The Inquisitr